Vascular Access Sales Specialist - WA, OR, ID, AK

ICU Medical reported record sales in Consumables and Infusion Systems during Q2 2026, with organic growth in Infusion Systems reaching 12%, driven by competitive wins and earlier-than-expected pump installations. The company raised its full-year adjusted EBITDA guidance to $415 million–$435 million and expects to reach a leverage ratio of approximately 2x by year-end. The firm received $21 million in tariff refunds during the quarter, boosting free cash flow, whilst incurring $21 million in restructuring expenses related to facility consolidations. Currency headwinds from the Costa Rican colon, Japanese yen, and Mexican peso have created a cumulative $60 million negative impact over four years. Management plans to resubmit its Medfusion 5000 syringe pump to the FDA this year and expects the Otsuka joint venture's new US facility to break ground on 24 August.

ICU Medical reported second-quarter results for 2026 that exceeded Wall Street expectations. The medical device company's revenue reached $551.7 million, up 1.5% year on year and beating analyst estimates of $532.8 million by 3.5%. The company's non-GAAP earnings of $2.37 per share surpassed consensus estimates of $1.91 by 23.8%. Adjusted EBITDA came in at $110 million, beating projections of $101.1 million. Operating margin improved to 7.1% from 4.9% in the same quarter last year. Free cash flow was $61.64 million, compared to negative $8.49 million a year earlier. For the full year, ICU Medical's adjusted EPS guidance of $8.80 at the midpoint exceeds analyst estimates by 7.8%. EBITDA guidance of $425 million also topped expectations of $417 million. Sell-side analysts project revenue growth of 3.3% over the next 12 months.

ICU Medical (NASDAQ:ICUI) reaches new 1-year high - what's next? July 28, 2026 Key points. * ICU Medical shares reached a new 52-week high, trading as high as $166.12 and recently up 2.9%. The stock has a market capitalization of approximately $4.15 billion. * Analyst sentiment is broadly positive, with a consensus "Buy" rating and an average price target of $172. Recent firms upgraded the stock to Buy or Strong Buy, although Piper Sandler lowered its target to $163. * ICU Medical exceeded quarterly expectations, reporting $1.97 in EPS versus the $1.78 consensus and revenue of $525.77 million. However, quarterly revenue declined 12.3% year over year, while two company insiders recently reduced their holdings through stock sales. * Five stocks we like better than ICU Medical. Shares of ICU Medical, Inc. (NASDAQ:ICUI - Get Free Report) hit a new 52-week high during trading on Tuesday. The stock traded as high as $166.12 and last traded at $167.8310, with a volume of 4195 shares traded. The stock had previously closed at $161.46. Analyst upgrades and downgrades. ICUI has been the subject of several research analyst reports. Jefferies Financial Group upgraded shares of ICU Medical to a "strong-buy" rating in a research note on Thursday, May 7th. Needham & Company LLC raised shares of ICU Medical from a "hold" rating to a "buy" rating and set a $165.00 target price on the stock in a research note on Wednesday, May 27th. BTIG Research initiated coverage on shares of ICU Medical in a report on Monday, June 15th. They issued a "buy" rating and a $170.00 price target for the company. Zacks Research raised shares of ICU Medical from a "hold" rating to a "strong-buy" rating in a research note on Monday, June 29th. Finally, Piper Sandler dropped their price objective on shares of ICU Medical from $178.00 to $163.00 and set an "overweight" rating on the stock in a report on Friday, April 17th. Three equities research analysts have rated the stock with a Strong Buy rating, four have issued a Buy rating and two have assigned a Hold rating to the stock. According to MarketBeat.com, ICU Medical has a consensus rating of "Buy" and an average target price of $172.00. ICU Medical stock up 2.9%. The company has a market cap of $4.15 billion, a price-to-earnings ratio of 89.95, a price-to-earnings-growth ratio of 2.20 and a beta of 0.76. The company has a debt-to-equity ratio of 0.60, a quick ratio of 1.17 and a current ratio of 2.34. The stock's fifty day moving average is $144.98 and its two-hundred day moving average is $139.78. ICU Medical (NASDAQ:ICUI - Get Free Report) last released its quarterly earnings results on Thursday, May 7th. The medical instruments supplier reported $1.97 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $1.78 by $0.19. The business had revenue of $525.77 million during the quarter, compared to the consensus estimate of $520.65 million. ICU Medical had a return on equity of 7.50% and a net margin of 2.15%.The company's quarterly revenue was down 12.3% on a year-over-year basis. During the same quarter in the previous year, the business earned $1.72 EPS. ICU Medical has set its FY 2026 guidance at 7.750-8.450 EPS. Sell-side analysts predict that ICU Medical, Inc. will post 6.51 earnings per share for the current fiscal year. Insider buying and selling at ICU Medical. In other ICU Medical news, Director David C. Greenberg sold 2,424 shares of the firm's stock in a transaction on Tuesday, May 12th. The stock was sold at an average price of $122.91, for a total transaction of $297,933.84. Following the transaction, the director directly owned 7,960 shares in the company, valued at approximately $978,363.60. This trade represents a 23.34% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, VP Virginia Ruth Sanzone sold 2,447 shares of ICU Medical stock in a transaction on Thursday, May 14th. The stock was sold at an average price of $124.08, for a total transaction of $303,623.76. Following the transaction, the vice president directly owned 19,460 shares in the company, valued at $2,414,596.80. This represents a 11.17% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Corporate insiders own 2.10% of the company's stock. Institutional trading of ICU Medical. Several institutional investors and hedge funds have recently made changes to their positions in ICUI. Hilton Head Capital Partners LLC purchased a new position in ICU Medical during the fourth quarter worth about $32,000. Covestor Ltd increased its stake in ICU Medical by 22.1% in the 4th quarter. Covestor Ltd now owns 696 shares of the medical instruments supplier's stock valued at $99,000 after buying an additional 126 shares during the last quarter. Strs Ohio lifted its position in shares of ICU Medical by 60.0% during the 4th quarter. Strs Ohio now owns 800 shares of the medical instruments supplier's stock worth $114,000 after buying an additional 300 shares in the last quarter. Rockefeller Capital Management L.P. lifted its position in shares of ICU Medical by 21.6% during the 4th quarter. Rockefeller Capital Management L.P. now owns 823 shares of the medical instruments supplier's stock worth $117,000 after buying an additional 146 shares in the last quarter. Finally, Kemnay Advisory Services Inc. purchased a new position in shares of ICU Medical in the 4th quarter worth approximately $120,000. Hedge funds and other institutional investors own 96.10% of the company's stock. ICU Medical company profile. ICU Medical, Inc, together with its subsidiaries, develops, manufactures, and sells medical devices used in infusion therapy, vascular access, and vital care applications worldwide. Its infusion therapy products include needlefree products under the MicroClave, MicroClave Clear, and NanoClave brands; Neutron catheter patency devices; ChemoClave and ChemoLock closed system transfer devices, which are used to limit the escape of hazardous drugs or vapor concentrations, block the transfer of environmental contaminants into the system, and eliminates the risk of needlestick injury; Tego needle free connectors; Deltec GRIPPER non-coring needles for portal access; and ClearGuard, SwabCap, and SwabTip disinfection caps. This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to [email protected]. Before you consider ICU Medical, you'll want to hear this. MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and ICU Medical wasn't on the list. While ICU Medical currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys. Tesla, Nvidia, and Google helped shape the last era of market growth, but the next wave could come from a new group of companies. Inside this report, you'll find 7 stocks that could play a major role in the next tech-driven market boom.